-
S.African activists push back on data centre rush
-
Billionaire Ambani's Jio jumps 21% in market debut after record India IPO
-
Billionaire Ambani's Jio to debut after record India IPO
-
Sri Lanka's Tamil farmers fight to reclaim land after civil war
-
UK set for cautious budget as borrowing costs climb
-
'They don't care about us': Trump food aid cuts leave Americans struggling and angry
-
US Fed expected to hold rates steady ahead of key midterm elections
-
Palestinian activist Khalil returns to Columbia after US detention
-
AI chip giant SK hynix says quarterly operating profit soars 630%
-
Youths testify about 'despair' in unprecedented Canadian climate trial
-
Charles tackles thorny legacy of slavery on Caribbean trip
-
Storied Paris department store seeks bankruptcy protection
-
UN nuclear watchdog chief urges Iran to grant access
-
Boeing shares tumble after it releases cautious growth forecast
-
Boeing releases cautious growth plan as shares fall sharply
-
Boeing reports smaller loss as it aims for stable output growth
-
Tech firms gain on Anthropic IPO optimism; HSBC slumps in London
-
Dangote, Nigeria's oil tycoon rewriting Africa's story
-
Tech firms track Wall St rally on mixed day for stock markets
-
Kane says Ballon d'Or win 'feels like a dream' as tributes pour in
-
HSBC profit jumps on higher rates, lower costs
-
Mercedes-Benz cuts 2026 profit outlook on tough China market
-
Reparations calls follow Charles on tough Caribbean trip
-
Wall Street faces earnings and Fed tests after turbulent technology-led week
-
China brands drop Mbappe for 'offending national sentiments'
-
Delhi grants minimum monthly pay and DA to about 4,000 MCD health workers
-
Critical coal inventories affect nearly half of India’s domestic power plants
-
FCNR(B) deposit drive puts sharper margin pressure on private banks
-
Gold ETF flows turn negative after 13 weeks as bullion loses 4%
Canada health authority approves Pfizer's anti-Covid pill
Canada's health authority said Monday it has approved Pfizer's anti-Covid pill, Paxlovid, for adults at high risk of progressing to serious disease.
The oral treatment was approved after an "expedited review," Health Canada said in a statement on its website, adding that it would continue to monitor its safety and effectiveness.
"No drug, including PAXLOVID TM, is a substitute for vaccination," the statement added.
The drug, which comprises two types of tablet, is the first Covid-19 therapy which can be taken at home, and is potentially a huge step towards ending the pandemic.
"Today's announcement is particularly important as access to easy-to-use treatments could help to reduce the severity of Covid-19 in adults who become newly infected and are at high-risk of progressing to serious illness," said Theresa Tam, Canada's chief public health officer.
The approval comes as Canada, like many countries, has been struggling to contain the Omicron variant of Covid-19.
The French-speaking province of Quebec recently announced it would levy a tax on the unvaccinated, arguing they impose a burden on everyone else.
Paxlovid has so far been authorized in a handful of countries including the United States and Israel, while the European Union has allowed member states to use it ahead of formal approval as an emergency measure against Omicron.
Unlike vaccines, it does not target the ever-evolving spike protein which the coronavirus uses to invade cells.
It should therefore in theory be more variant-proof, and the company has said preliminary lab studies have backed up that hypothesis.
S.F.Lacroix--CPN